Caitong International Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

Caitong International Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28	Buy	+7	New	+$36	﹤0.01%	2455

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's KLRS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 7 shares worth $28. The stake represents ﹤0.01% of the portfolio and ranks #2455 among its holdings.

57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

Caitong International Asset Management held 7 shares of Kalaris Therapeutics worth $28 as of Q2 2026.
Kalaris Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Kalaris Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2455 holding.
57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.